$CING Cingulate Inc Target PT 33 and higherNASDAQ:CING Cingulate Inc
Target PT 33 and higher
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), whi